Our Grants - Helmsley Charitable Trust

GRANT	DATE	AMOUNT	PROGRAM
American Gastroenterological Association Institute Amplifying Learning from the Cedars-Sinai Advanced Dietary IBD Education and Training (DIET) Program: Beyond Malnutrition	05.09.2023	$138,957.00	Crohn's Disease, Disease Management
Cornell University Sponsorship for the 25th anniversary Adherent Invasive E. coli (AIEC) meeting	04.12.2023	$15,000.00	Crohn's Disease, Diagnostics
The Imperial College of Science, Technology and Medicine Unraveling the immunopathology of perianal fistulizing Crohn's disease	02.08.2023	$3,111,800.00	Crohn's Disease, Disease Biology
Johns Hopkins University Engineered Cytokine/Antibody Fusion Protein to Treat Crohn's Disease	02.08.2023	$1,500,000.00	Crohn's Disease, Therapeutics
The Regents of the University of California, San Diego The Druggable GPCRome in Crohn's Disease	02.08.2023	$3,494,185.00	Crohn's Disease, Therapeutics
Cornell University for the Joan & Sanford I. Weill Medical College of Cornell University Targeting the mycobiome in patients with Crohn's Disease	02.08.2023	$1,929,856.00	Crohn's Disease, Therapeutics
Regents of The University of Michigan Evaluation of a Gut-Specific Antifibrotic Therapeutic in Pre-clinical Models of Crohn's Disease	01.25.2023	$558,806.00	Crohn's Disease, Therapeutics
Washington University Cellular biomarkers for pediatric Crohn's disease	01.25.2023	$1,015,114.00	Crohn's Disease, Diagnostics
London North West University Healthcare NHS Trust Perianal Crohn's Disease Consortium	01.25.2023	$69,442.00	Crohn's Disease, Diagnostics
The Broad Institute, Inc. Uncovering Crohn's genetic risk in African-American and Hispanic/Latino populations	01.25.2023	$3,057,442.00	Crohn's Disease, Disease Biology
Children's Hospital Medical Center Role of PPAR-alpha in promoting brush border maturity of intestinal enterocytes	01.25.2023	$838,931.00	Crohn's Disease, Disease Biology
Chancellor Masters & Scholars Of The University Of Oxford Interrogating the mechanism of hypersensitivity to antibody-based drugs for development of a novel anti-TNF biologic for Crohn's disease	12.20.2022	$474,279.00	Crohn's Disease, Therapeutics
Clalit Health Services Israeli IBD Research Nucleus (IIRN) Consortium Management	11.08.2022	$422,087.00	Crohn's Disease, Other
Clalit Health Services Israeli IBD Research Nucleus (IIRN) Consortium: Biomarker-Based Multidisciplinary Team Approach to Improve Early Crohn's Disease Outcomes	11.08.2022	$1,360,291.00	Crohn's Disease, Other
The Sheba Fund for Health Services and Research (R.A.) Israel IBD Research Nucleus (IIRN) Consortium: Capsule & Omics for pRedicting Exacerbation of Crohn's disease (CORE-CD)	11.08.2022	$2,447,647.00	Crohn's Disease, Other
Rambam Health Corporation Israeli IBD Research Nucleus (IIRN) Consortium: Microbial and Dietary Effects on Immune Composition and Function in Patients with Crohn's disease: Spatial Microbial Cellular Interactions & Effects on Immunogenicity	11.08.2022	$2,885,540.00	Crohn's Disease, Other
Shaare Zedek Medical Center Israeli IBD Research Nucleus (IIRN) Consortium: Combining Multi-Tier Administrative Data for Facilitating Disease Free Management	11.08.2022	$3,066,299.00	Crohn's Disease, Other
Ben-Gurion University of the Negev Israeli IBD Research Nucleus (IIRN) Consortium: COBMINDEX goes forward- A Smartphone application for added psychological wellbeing in Crohn's disease.	11.08.2022	$2,770,874.00	Crohn's Disease, Other
The Weizmann Institute of Science Decoding the clinical impact of host and microbial intestinal proteomic landscape in Crohn's disease	11.08.2022	$1,662,735.00	Crohn's Disease, Diagnostics
The Chancellor, Masters and Scholars of the University of Cambridge Epigenetic regulation of intestinal epithelial MHC class 1 signalling - a novel mechanism in the pathogenesis of Crohn's Disease	11.08.2022	$2,142,788.00	Crohn's Disease, Disease Biology
You can filter rows: 1 - 20 of 224 < > Last